INDICATIONS EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...

Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, ...

In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of ...

Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline ...

A new study published in Clinical & Experimental Ophthalmology found that faricimab was effective in treating patients with neovascular age-related macular degeneration (nAMD) who had not previously ...

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ...

Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 ...

D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of the Company’s product candidates are in clinical or preclinical development and have ...

Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.